3 Strong-Buy

Penny Stocks You Should
Be Watching!

4 Strong-Buy Penny Stocks You Should Be Watching!

.....

Nasdaq and OTC market penny stocks are benefiting from the current frothy nature of the broader markets, enjoying a “Golden Age” as different sector cycles fuel significant rallies.

Wall Street’s sweet spot is stocks that trade below $10 a share. The Street’s cranking out several small-cap stocks that gain more than 100%, just about every day, so it’s easy to feel FOMO.

In this market, volatility can be your best friend—but only if you know how to take advantage of it ahead of everyone else.

In addition to volatility, investors and traders spend considerable time selecting indicators for their entries, such as VWAP tests, 9EMA bounces, MACD crossovers, and more.

However, sometimes the clearest indicator of future potential are the companies’ explicit hints of upcoming developments in press releases.

Trader Alert: VENU Breaks Out

Vanguard In, Cenorium Strong Buy to $22, Northland Ups Target to $17

BREAKING:

As I have predicted additional institutions have put $30 million into VENU! At $12 a share, which gives my readers an opportunity to participate before it climbs back up to the recent high of $18

Cenorium maintains its Strong Buy alert up to $22. Northland Securities raises its price target to $17 (from $15) and reiterates a “BUY.” Vanguard takes a 2.3% stake retail still has room before more institutions pile in. August 18, 2025 Venu Holding Corporation NYSE:VENU (“VENU”) just delivered Q2 results that traders can’t ignore: surging assets, institutional validation, and a national pipeline built for expansion. The Big Catalyst: Vanguard disclosed a 2.3% stake (861,911 shares, $13M). That early institutional entry validates the story and sets the stage for broader Wall Street adoption, index inclusion, and more analyst coverage. Additional $10mill from Aramark at around $15, And now $30mill from additional institutions!

“As we close out this quarter, we’re seeing the pieces come together, for what’s going to be a defining moment in our growth history.”

– J.W. Roth, Founder & CEO

Q2 Trader Highlights

  • Assets: Up 36% to $242M.
  • Property & Equipment: $199M, up 45%, reflecting multi-state builds.
  • FireSuite & Club Sales: $61.3M YTD (+34% YoY).
  • Ford Amphitheater: 35,000+ fans, $4.7M gross receipts, avg. ticket $135.

Pipeline & Profit Drivers

  • 38 municipalities in talks; Ryan, LLC partnership aiming for 2 new deals per quarter ($150M–$300M each).
  • Sunset Amphitheater (TX): 20,000 seats, opening 2026.
  • Sale-Leaseback Deal: Expected $188M inflow, $35M profit in Q4 2025, plus another $35M in Q4 2026.
  • Triple-Net Lease Program projected to add $100M+ annually.

Analyst & Retail Setup

  • Cenorium: Strong Buy rating up to $22.
  • Northland Securities: Raised price target to $17 (from $15), maintaining BUY.
  • Market cap over $600M VENU is no longer a micro-cap, opening the door to institutional ownership and small-cap index potential. (temp drop after $12 funding.
  • Vanguard and others are in, retail investors still have room before the institutions load up.

Strategic Partnerships

  • Expanded Aramark Sports + Entertainment partnership.
  • New Billboard alliance, including the VENU Disruptor Award.
  • Triple-net leasing with Sands Investment Group already exceeding forecasts.

About WallStreet-PR
Wallstreet-PR has been covering the markets since 1999. We deliver market-moving news, stock alerts, and coverage of small-cap and emerging growth companies. Our alerts are free and only sent when news warrants your attention.

Compensated for the distribution of this content. Investing in stocks involves risk, including the potential loss of principal. Always consult with a licensed financial advisor before making investment decisions.

Here are THREE STOCKS 
with IMMINENT CATALYSTS
that could soon become some of the most talked-about names in the small-cap market:

Spider Silk Super Fibers,Coming Soon!

Kraig Biocraft Laboratories Inc. (OTC:KBLB)

Readers,

If you love true pennies, this stock is definitely one to watch. I’ve been covering KBLB for many years, and they are on the verge of completing their first commercial production order of Spider Silk, ready to ship. Exciting times indeed….

The company recently announced it’s in production to fulfill its first commercial order for Spider Silk using its proprietary BAM-1 hybrid technology. Kraig’s (KBLB) first commercial order is expected to be shipped to an unnamed, globally renowned European fashion house, likely a very “famous” brand.

Once completed, the company will notch its first commercial sale, proving the efficacy of its Spider Silk technology production platform using transgenic silkworms.

As a reminder, spider silk has long been one of the most sought-after natural fibers due to its unmatched combination of strength, elasticity, and lightness. It’s five times stronger than steel by weight and more flexible than Kevlar, while also being biocompatible and biodegradable. These performance traits make it highly valuable across industries spanning defense, aerospace, medical devices, textiles, and other high-performance applications.

On August 21st, Kraig Biocraft Laboratories (OTC:KBLB) announced its second production rearing center in Southeast Asia is now fully operational. With two facilities running in parallel, the company can ensure continuous rearing cycles, greater scalability, and more consistent output. Teams are working with established BAM-1 parental lines as well as three new genetic lines introduced this summer, which are expected to boost breeding capacity and production efficiency.

From a technical perspective, the long-term chart suggests that press events such as the news of who the order is for could create a launchpad event for KBLB.

It’s definitely better for investors to be positioned ahead of upcoming news like this, as depending on who the order is with, and given the stock doesn’t trade pre-market, KBLB would likely reprice quickly on the day of the announcement. That would hand most of the gains to algos and funds, leaving traders and investors chasing.

For those new to Kraig, I encourage you to watch the company’s videos on YouTube, read through their recent press releases, and even fire up your favorite LLM to research spider silk itself—you’ll quickly see why this breakthrough material has captured the attention of scientists, brands, and investors alike.

Kraig Biocraft Laboratories Inc.
(OTC:KBLB)

Analyst Report says this stock is at least 25X undervalued right now…

...but probably not for much longer

(NASDAQ: XHLD) is trading well under $1, yet analysts see a path to $8/share as the Company pivots into an AI-powered, cloud-based PaaS platform that could democratize high-end production for live streaming. From Fortune 500 conferences with 80,000 attendees to creators on YouTube and Twitch, Ten Holdings’ new Ten Pro platform gives anyone commercial-grade studio tools—without the heavy crews or costs.

Litchfield Research’s Barry Sine (Twice Wall Street Journal All-Star Analyst winner, 2X Financial Times All-Star Analys winner, and top 5% global stock-picking- TipRanks) calls this a transformational moment, suggesting shares could soar as high as $8. That’s a potential 500%–2500% profit zone for traders accumulating around these levels.

Remember, one of my last calls made a similar run—shooting from $0.98 to nearly $9.50 on record volume. Moves like that don’t come often, but XHLD is lining up the same kind of setup.

Here’s why it matters:

  • Ten Holdings is shifting from a labor-heavy event services model into a recurring SaaS revenue engine.
  • Cloud-based automation streamlines massive productions into a single dashboard.
  • Fortune 500 clients already trust them—now the creator economy is wide open.
  • XHLD has been quietly consolidating below $0.50 all summer while preparing this launch.

With catalysts on deck and the buzz around Cloud + AI integrations, the breakout zone above $1.30 could come fast and once that happens, the move higher could surprise the markets.

Summer is over, everyone is back to school, it’s time for Mayhem in the markets!

XHLD– trade plan, buying up to $1.30

As always—trade with a plan, read the PRs, and stay nimble. The stage is set.

DISCLOSURE: WallStreet-PR.com (WSTPR), owns and operates wallstreet-pr.com is a third-party publisher and news release service provider which disseminates corporate news electronically through multiple online media platforms. WSTPR is NOT an affiliate with any of the companies mentioned in our reports. WSTPR is a news distribution service and is not registered with FINRA or any other professional licensing service. WSTPR is not an analyst, broker dealer or advisor, and holds no such licenses. WSTPR may NOT offer to buy, sell, or hold any security. WSTPR corporate profiles will NEVER be a solicitation or recommendation of any kind, of any security mentioned. The materials in all our releases are intended to be for informational purposes only and should never be considered research or due diligence on any company mentioned. All readers are encouraged to perform standard due diligence by reading the company’s filings at SEC.gov. Readers should consult their broker or licensed professional before investing in any company. All materials in this release are based on publicly available statements made by the companies. WSTPR is not liable for any investment decisions made by any readers or subscribers. Any investment could result in you losing all your money from investing in any stock. WSTPR’s editor owns no shares of SYTA restricted shares of Kraig Labs no shares of Venu holdings and no shares of any of the other mentioned companies. The editors of WSTPR can trade in these stocks at any time on news or technical analysis indicators and will not update with position size, entry’s or exits. Trade any of these stocks at your own risk. You should know this is a conflict of interest. Publisher charges $1,000 per editorial press release on WSTPR, and is contracted by Micro Cap Advisory for editorial coverage, and traffic to this web site for Ten Holdings, Venu Holdings and LIXTE biotechnology and could spend up to twenty thousand dollars a week each on investor awareness. WSTPR’s editors have also been contracted to write editorials about Kraig Labs by KAROLUS, who is contracted directly with the company and owns restricted non tradable shares and receives cash compensation for the distribution of this report. WSTPR will also be using financial marketing tools and platform to enhance distribution of this report. WSTPR and its editors own no shares of any other stocks in this editorial and will not be trading in PLANTIR, APPLOVIN, SIYATA or KRAIG unless disclosed herein. Editors are paid to put a best-case scenario profile out to the investing public. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WSTPR undertakes no obligation to update such statements. WallStreetPR.com is a news and opinion website operating under the protections of the First Amendment to the United States Constitution. The content on this site represents the views and opinions of its authors and is intended for informational purposes only. Any sponsored content will be clearly disclosed, and all readers are encouraged to perform their own due diligence before making investment decisions. WallStreetPR does not offer investment advice or securities recommendations.